CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

11144	Companies
245608	Keywords
173680	Articles
132557	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 05/20/2025 at 07:30, 1 year 4 months ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
PRESS RELEASE

published on 05/20/2025 at 07:30, 1 year 4 months ago

CROSSJECT prépare le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription d’un montant d’environ 5 millions d’euros en préparation des activités commerciales et de production liées à l’approbati
CROSSJECT lance une augmentation de capital de 5 millions d'euros pour soutenir ses activités commerciales et de production liées à l'approbation EUA de ZEPIZURE®

Augmentation De Capital Crossject ZEPIZURE® Activités Commerciales Approbation EUA
BRIEF

published on 05/07/2025 at 07:35, 1 year 5 months ago

CROSSJECT : Progrès dans la demande d'autorisation EUA pour ZEPIZURE®

FDA ZEPIZURE® BARDA EUA CHEMPACK
BRIEF

published on 05/07/2025 at 07:35, 1 year 5 months ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
PRESS RELEASE

published on 05/07/2025 at 07:30, 1 year 5 months ago

CROSSJECT fait un point sur les dernières avancées dans le dépôt de la demande EUA de ZEPIZURE®
CROSSJECT provides updates on the EUA filing of ZEPIZURE® for FDA Emergency Use Authorization in June 2025, supporting U.S. CHEMPACK program against chemical threats

FDA Crossject ZEPIZURE EUA Filing CHEMPACK Program
BRIEF

published on 03/27/2025 at 07:35, 1 year 6 months ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
BRIEF

published on 03/27/2025 at 07:35, 1 year 6 months ago

CROSSJECT publie ses résultats financiers 2024

Résultats Financiers Partenariats Situation De Trésorerie ZEPIZURE® Dépôt Auprès De La FDA
PRESS RELEASE

published on 03/27/2025 at 07:30, 1 year 6 months ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 1 year 6 months ago

Partenariat stratégique entre CROSSJECT et ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Insuffisance Surrénale
BRIEF

published on 03/25/2025 at 07:35, 1 year 6 months ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency

Accesswire

Published on 10/07/2026 at 17:00, 4 hours 25 minutes ago

BlackBerry Radar Expands Asset Intelligence Platform with Dynamic Pairing
Published on 10/07/2026 at 15:30, 5 hours 55 minutes ago

Gold Port Announces Marketing Agreement with NAI Interactive Ltd.
Published on 10/07/2026 at 14:30, 6 hours 55 minutes ago

Secure Blockchain's Agentic Solutions Signs Financial Services Firm, Expanding Enterprise AI Into Corporate Finance
Published on 10/07/2026 at 13:33, 7 hours 52 minutes ago

BULGOLD Samples 21.2g/t Gold at Surface and Expands Kopernica Footprint by 170% to 1,700 Metres by 800 Metres, Lutila Project
Published on 10/07/2026 at 13:00, 8 hours 25 minutes ago

ATHA Energy Successfully Completes Diamond Drilling at RIB North Discovery, Expanding Strike Length To 3.4 Km, And Identifies a Higher-Grade Sub Zone: Results Include RIBN-DD-023 Intersecting 19.5 M Of Composite Uranium Mineralization With 2.0 M Of High-G

View all ACCESSWIRE

EQS Group

Published on 10/07/2026 at 20:55, 29 minutes ago

innoscripta SE Initiates Independent External Investigations to Clarify the Facts Underlying the Authorities’ Investigations and Review Clusterix’s Documentation and Control Mechanisms
Published on 10/07/2026 at 18:30, 2 hours 55 minutes ago

IEVA GROUP: rappel – Visioconference actionnaires et investisseurs jeudi 15 octobre 2026 - 18h00 (CEST)
Published on 10/07/2026 at 18:15, 3 hours 10 minutes ago

VAZIVA SA: 2026 HALF-YEAR RESULTS - A half-year of strategic investments to prepare a new growth cycle
Published on 10/07/2026 at 18:00, 3 hours 25 minutes ago

EUROPLASMA: Réduction de capital et regroupement des actions Europlasma
Published on 10/07/2026 at 17:44, 3 hours 40 minutes ago

BILENDI: Half-year 2026 Results: Continued execution of the strategic plan in a challenging market environment

Les Echos

Published on 10/07/2026 at 20:15, 1 hour 9 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 10/07/2026 at 20:15, 1 hour 10 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 10/07/2026 at 20:15, 1 hour 10 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES SEPTEMBRE 2026
Published on 10/07/2026 at 20:15, 1 hour 10 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES SEPTEMBRE 2026
Published on 10/07/2026 at 18:19, 3 hours 5 minutes ago

Outstanding shares and voting rights statement at 30 September 2026

View all LES ECHOS COMFI WIRE